Program
CS-001
A development code.
Its studies are led by Applied Biology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Applied Biology | 11 open or running | phase 3since Dec 17, 2024 | Dec 17, 2024 | Dec 15, 2027phase 3 · NCT06745336 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2024First study: phase 3 study in CanitiesFirst studyNCT06745336 · 240 planned
- Nov 2, 2026Primary completion moved from 2027-06-15 to 2027-12-15Date moved laterphase 3 · +6 months · NCT06745336
Ahead
- Dec 15, 2027Primary completion: phase 3 study in CanitiesNCT06745336
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06745336Canities | 3 | Not yet recruiting | Dec 15, 2027 | 240 |
How it is read
Names in the registry
- “CS-001”, 1 entry
Codes read as this program: CS001.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.